NB Therapeutics is a biopharmaceutical and medical device company focused on developing and commercializing novel and proprietary pharmacologic therapies to address opportunities in the dermatology and podiatry markets with significant unmet needs.
NB Therapeutics has two technology platforms: iontophoresis and nitric oxide gas. Through these two technology platforms, NB Therapeutics seeks to address the inherent challenges of drug delivery for diseases of the skin and nails.
The company has advanced compounds from both of its technology platforms to human clinical trials. Nitric Bio’s lead compound in development is a patented, ionized formulation of terbinafine which is delivered to the nail and nail bed through iontophoresis for the treatment of onychomycosis.
A Phase 2 clinical trial of the company’s proprietary drug/device combination for the treatment of onychomycosis is currently ongoing, with six month analysis anticipated to be available in the first half of 2011.